查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1937784

全球肌萎縮側索硬化症治療市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Amyotrophic Lateral Sclerosis Treatment Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 136 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

肌萎縮側索硬化症 (ALS) 治療市場規模預計將從 2025 年的 8.0136 億美元成長到 2034 年的 12.6033 億美元，2026 年至 2034 年的複合年成長率為 5.16%。

肌萎縮側索硬化症 (ALS) 治療市場正經歷顯著成長，這主要得益於這種神經退化性疾病盛行率的不斷上升以及治療方案的不斷進步。 ALS 的特徵是運動神經元進行性退化，其複雜的病理學為治療帶來了獨特的挑戰。然而，近年來，疾病修正治療（例如Riluzole和Edaravone）的進展已顯示出在延緩疾病進展和改善患者預後方面令人鼓舞的結果。對包括基因療法和幹細胞療法在內的新型治療方法的持續研究，正在進一步擴展 ALS 治療的前景。

此外，人們對肌萎縮側索硬化症（ALS）的認知不斷提高，以及相關專案研究計劃的開展，推動了對有效治療方法的需求。倡導團體和組織在提高公眾意識和資金籌措發揮關鍵作用，從而促進了對ALS治療的投入。同時，個人化醫療的興起也影響ALS治療市場，臨床醫師致力於根據患者的個別特徵和遺傳因素調整治療方案。這種方法旨在提高治療效果，並滿足每位患者的獨特需求。

此外，多學科診療模式的整合正在改變肌萎縮側索硬化症（ALS）的治療管理。神經科、物理治療師、職業治療師和營養師的協作對於提供全面護理至關重要，能夠應對ALS患者面臨的各種挑戰。這種整體性方法不僅能提高患者的生活品質，還能在整個疾病歷程中為患者及其家人提供支持。總之，ALS治療市場有望迎來強勁成長，其特點是創新、公眾意識的提高以及致力於改善這一充滿挑戰的治療領域的患者照護。

目錄

第1章 引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 繪製滲透率和成長前景圖
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制
    • 市場機遇
    • 市場問題
  • 波特五力分析
  • PESTLE分析

4. 全球肌萎縮側索硬化症治療藥物市場

  • 市場分析、洞察與預測
  • Riluzole
  • Edaravone
  • 其他

5. 全球肌萎縮側索硬化症治療市場（按類型分類）

  • 市場分析、洞察與預測
  • 散發性肌萎縮性側索硬化症
  • 遺傳性肌萎縮性側索硬化症

6. 全球肌萎縮側索硬化症治療市場（依分銷管道分類）

  • 市場分析、洞察與預測
  • 醫院藥房
  • 線上供應商
  • 藥局和零售藥房

7. 全球肌萎縮側索硬化症治療市場（按地區分類）

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第8章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商格局（基於現有資訊）
  • 策略規劃

第9章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Alkem Laboratories Ltd
    • Aquestive Therapeutics Inc
    • Italfarmaco SPA
    • Viatris Inc
    • Mitsubishi Chemical Group Corporation
    • Amylyx Pharmaceuticals Inc
    • Otsuka Pharmaceutical Co. Ltd
    • Glenmark Pharmaceuticals Limited
    • Covis Pharma GmbH
    • Sun Pharmaceutical Industries Ltd
簡介目錄
Product Code: VMR11216729

The Amyotrophic Lateral Sclerosis Treatment Market size is expected to reach USD 1260.33 Million in 2034 from USD 801.36 Million (2025) growing at a CAGR of 5.16% during 2026-2034.

The amyotrophic lateral sclerosis (ALS) treatment market is witnessing significant growth, driven by the increasing prevalence of this neurodegenerative disease and advancements in therapeutic options. ALS, characterized by the progressive degeneration of motor neurons, presents unique challenges in treatment due to its complex pathophysiology. However, recent developments in disease-modifying therapies, such as riluzole and edaravone, have shown promise in slowing disease progression and improving patient outcomes. Ongoing research into novel therapeutic approaches, including gene therapy and stem cell treatments, is further expanding the landscape of ALS management.

Moreover, the growing awareness of ALS and the establishment of dedicated research initiatives are propelling the demand for effective treatment options. Advocacy groups and organizations are playing a crucial role in raising awareness and funding research, leading to increased investment in ALS therapies. Additionally, the focus on personalized medicine is influencing the ALS treatment market, as clinicians seek to tailor interventions based on individual patient profiles and genetic factors. This approach aims to enhance treatment efficacy and address the unique needs of each patient.

Furthermore, the integration of multidisciplinary care models is transforming the management of ALS. Collaborative approaches involving neurologists, physical therapists, occupational therapists, and nutritionists are essential for providing comprehensive care that addresses the diverse challenges faced by ALS patients. This holistic approach not only improves quality of life but also supports patients and their families throughout the disease journey. In conclusion, the ALS treatment market is set for robust growth, characterized by innovation, increased awareness, and a commitment to improving patient care in this challenging therapeutic area.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drugs

  • Riluzole
  • Edaravone
  • Others

By Type

  • Sporadic ALS
  • Familial ALS

By Distribution Channel

  • Hospital Pharmacies
  • Online Providers
  • Drug Stores and Retail Pharmacies

COMPANIES PROFILED

  • Alkem Laboratories Ltd, Aquestive Therapeutics Inc, Italfarmaco SPA, Viatris Inc, Mitsubishi Chemical Group Corporation, Amylyx Pharmaceuticals Inc, Otsuka Pharmaceutical Co Ltd, Glenmark Pharmaceuticals Limited, Covis Pharma GmbH, Sun Pharmaceutical Industries Ltd

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET: BY DRUGS 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Drugs
  • 4.2. Riluzole Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Edaravone Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET: BY TYPE 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Type
  • 5.2. Sporadic ALS Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Familial ALS Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Distribution Channel
  • 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Online Providers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Drug Stores and Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET: BY REGION 2022-2034(USD MN)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.2.1 By Drugs
    • 7.2.2 By Type
    • 7.2.3 By Distribution Channel
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.3.1 By Drugs
    • 7.3.2 By Type
    • 7.3.3 By Distribution Channel
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Russia
    • 7.3.9 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.4.1 By Drugs
    • 7.4.2 By Type
    • 7.4.3 By Distribution Channel
    • 7.4.4 India
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 Australia
    • 7.4.8 South East Asia
    • 7.4.9 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.5.1 By Drugs
    • 7.5.2 By Type
    • 7.5.3 By Distribution Channel
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 South East Asia
    • 7.5.9 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.6.1 By Drugs
    • 7.6.2 By Type
    • 7.6.3 By Distribution Channel
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 Alkem Laboratories Ltd
    • 9.2.2 Aquestive Therapeutics Inc
    • 9.2.3 Italfarmaco S.P.A
    • 9.2.4 Viatris Inc
    • 9.2.5 Mitsubishi Chemical Group Corporation
    • 9.2.6 Amylyx Pharmaceuticals Inc
    • 9.2.7 Otsuka Pharmaceutical Co. Ltd
    • 9.2.8 Glenmark Pharmaceuticals Limited
    • 9.2.9 Covis Pharma GmbH
    • 9.2.10 Sun Pharmaceutical Industries Ltd